GlassScriptPhysician profile
Elizabeth A Orwick
NPI 1053407213
$6,712.94
in general payments reported to CMS, 2019-2025
36 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $87.77 · 2021: $2,804 · 2022: $1,091 · 2023: $1,504 · 2024: $559 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,410 · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.84 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,556.96 | 2019-2021 | |
| Abbvie INC. | $846.15 | 2019-2025 | |
| Myriad Women'S Health, INC. | $392.87 | 2023 | Myrisk |
| Pfizer INC. | $328.96 | 2023-2025 | |
| Daiichi Sankyo INC. | $314.19 | 2021-2025 | Injectafer |
| Mayne Pharma Commercial LLC | $231.74 | 2022-2025 | |
| Aspira Women'S Health INC | $196.02 | 2021-2024 | Ova1 |
| Exeltis, USA INC. | $171.62 | 2019-2025 | Slynd |
| Therapeuticsmd, INC. | $169.22 | 2019-2022 | |
| Agile Therapeutics, INC. | $137.15 | 2021-2024 | Twirla |
| Biohaven Pharmaceutical Holding Company LTD. | $132.96 | 2022 | |
| Astellas Pharma US INC | $112.55 | 2022-2024 | Veozah, Myrbetriq |
| Mylan Pharmaceuticals INC. | $92.51 | 2021-2022 | |
| Channel Medsystems, INC. | $86.49 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.78 | 2022-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $77.85 | 2022-2023 | Myosure Tissue Removal Device, Coolseal Generator, Novasure |
| Evofem Biosciences, INC. | $75.81 | 2021-2022 | |
| Organon LLC | $72.59 | 2022-2024 | |
| Myovant Sciences INC. | $72.08 | 2021 | |
| Biogen, INC. | $57.09 | 2024 | Zurzuvae |
| Coopersurgical, INC. | $56.68 | 2019-2025 | Paragard T 380a |
| Minerva Surgical, INC | $55.91 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $53.35 | 2024-2025 | Exparel, Zilretta, Iovera |
| Novo Nordisk INC | $46.93 | 2024-2025 | Wegovy |
| Visby Medical, INC. | $38.80 | 2023 | Visby Medical Sexual Health Click Test |
| Scynexis, INC. | $38.34 | 2022 | |
| Lilly USA, LLC | $38.15 | 2025 | Zepbound, Mounjaro |
| Biohaven Pharmaceuticals, INC. | $35.50 | 2021 | |
| Gynesonics, INC. | $29.82 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Ethicon US, LLC | $28.06 | 2023 | Dermabond Prineo, Stratafix |
| Exact Sciences Corporation | $23.23 | 2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $21.23 | 2024 | |
| Lsi Solutions INC | $14.74 | 2023 | Fornisee |
| Medtronic, INC. | $12.69 | 2022 | |
| Lupin INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Orwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.